1075 Development of WTX-712, a conditionally active IL-21 INDUKINETM molecule for the treatment of cancer

• Kyriakos Economides,
• Nesreen Ismail,
• Andres Salmeron,
• Jenna M Sullivan,
• Pam Aderhold,
• Heather R Brodkin,
• Celesztina Nagy-Domonkos,
• Daniel J Hicklin,
• Cynthia Seidel-Dugan,
• William M Winston

Affiliations

Kyriakos Economides

Codiak BiSciences, Cambridge, MA, USA

Nesreen Ismail

1Werewolf Therapeutics, Cambridge, MA, United States

Andres Salmeron

Werewolf Therapeutics, Cambridge, MA, United States

Jenna M Sullivan

Werewolf Therapeutics, Watertown, MA, USA

Pam Aderhold

Werewolf Therapeutics, Watertown, MA, USA

Heather R Brodkin

Werewolf Therapeutics, Watertown, MA, USA

Celesztina Nagy-Domonkos

Werewolf Therapeutics, Watertown, MA, USA

Daniel J Hicklin

Werewolf Therapeutics, Watertown, MA, USA

Cynthia Seidel-Dugan

Werewolf Therapeutics, Watertown, MA, USA

William M Winston

Werewolf Therapeutics, Watertown, MA, USA